Rxwire
In the news · 48h FDA 38 Eli Lilly 21 Roche 11 Johnson & Johnson 7 Merck & Co. (MSD) 7 AstraZeneca 3 Daiichi Sankyo 3 Bayer 2
Trials & R&D · first seen 3h ago, updated 3h ago

Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors

1 outlet

Syndax Pharmaceuticals Inc. has identified menin (M)/KMT2A (MLL) interaction inhibitors reported to be useful for the treatment of cancer.

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

  1. BioWorld Articles
    Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors